Anti-tTg-IgA is neither a Solved Problem nor a “closed case” in Celiac Disease Diagnosis

Aaron Lerner^{1, 2,} , Sandra Neidhöfer² and Torsten Matthias²

¹B. Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa, Israel

²AESKU.KIPP Institute, Wendelsheim

Cite this paper:
Aaron Lerner, Sandra Neidhöfer and Torsten Matthias. Anti-tTg-IgA is neither a Solved Problem nor a “closed case” in Celiac Disease Diagnosis. International Journal of Celiac Disease. 2017; 5(3):97-100. doi: 10.12691/ijcd-5-3-1

Abstract

Anti-tissue transglutaminase (tTg) IgA are considered the most frequently used serological marker for celiac disease diagnosis. Despite its recommended leading position by the 2012 ESPGHAN diagnostic criteria, it exposes multiple false positive and negative titers. In view of the critical opinions expressed lately in the literature against the application of those criteria, the bias in the central place occupied by tTg-IgA in the new ESPGHAN CD Diagnostic Guidelines and the emergence of newer serological marker for celiac disease, it is hoped that the revised guidelines will open up the limited, problematic and single Tg2-IgA antibody for other or additional single or combined serological diagnostic markers.

Keywords:
celiac disease antibody diagnosis tissue transglutaminase neo-epitope microbial transglutaminase

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Lerner A, Jeremias P, Matthias T. The world incidence of celiac disease is increasing: a review. Internat. J. Of Recent Scient. Res. 2015;7:5491-5496.
[2]	Lerner A, Jeremias P, Matthias T. The world incidence and prevalence of autoimmune diseases is increasing: A review. Internat. J. Celiac Dis. 2015;3:151-155.
[3]	Lerner A., Reif, S. Nonnutritional environmental factors associated with Celiac disease: The Infectome. In: Infections and Autoimmunity. Eds: Shoenfeld, Y., Agmon-Levine, N., Rose, N.R. 2nd Ed.Elsevier B.V. 2015, Chapter 50, pages 829-837.
[4]	Lerner, A., Blank, M. Hypercoagulability in celiac disease-an update. Autoimmun. Rev. 2014;13:1138-41.
[5]	Lerner A, Makhoul B, Eliakim R. Neurological manifestations of celiac disease in children and adults. Eur. Neurolog. J. 2012;4: 15-20.
[6]	Lerner A, Matthias T. Rheumatoid arthritis-celiac disease relationship: joints get that gut feeling. Autoimm. Rev. 2015;14:1038-47.
[7]	Lerner A, Matthias T. Increased knowledge and awareness of celiac disease will benefit the elderly. Internat. J. of Celiac Dis. 2015;3:112-114.
[8]	Lerner A, Matthias T. Editorial: Celiac disease: intestinal, heart and skin inter-connections. Internat. J. Celiac Dis.2015: 3:28-30.
[9]	Lerner A, Matthias T. Gut-bone cross talks and implications in celiac disease. Internat. J. Celiac Dis, 2016;4:19-23.
[10]	Lerner A, Matthias T. The Gut-stomach Axis: Helicobacter pylori and Celiac Disease. Internat. J. Celiac Dis. 2016; 4:77-79.
[11]	Lerner A, Matthias T. Extraintestinal manifestations of CD: Common pathways in the gut-remote organs’ axes. Internat J Celiac Dis. 2017;5:24-27.
[12]	Lerner A, Jeremias P, Matthias T. The gut-thyroid axis: beyond the thyroid: what’s happening in the gut. Endocrinol Connections, in press, 2017.
[13]	Lerner A, Berthelot L, Jeremias P, Abbad L, Matthias T, Monteiro RC. Gut-kidney axis: gluten, transglutaminase, celiac disease and IgA nephropathy J Clin Cell Immunol, 2017;8: In Press
[14]	Eliyah Livshits O, Shauol R, Reifen R, Matthias T. Lerner A. Can Celiac Disease Present Along With Childhood Obesity? Internat J Celiac Dis. 2017;5:19-23.
[15]	Villanueva M, Rojas M, Araya M. IgA and IgG Anti-transglutaminase 2 Antibodies in the Diagnosis of Celiac Disease. Internat J Celiac Dis, 2017;5(2):43-47.
[16]	Husby S, Koletzko S, Korponay-Szabo IR, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. Journal of pediatric gastroenterology and nutrition. 2012;54:136-160.
[17]	Lerner A, Jeremias P, Neidhöfer S, Matthias T. Comparison of the reliability of 17 celiac disease associated bio-markers to reflect intestinal damage. J of Clin & Cell Immunology. 2017;8: 1.
[18]	Lerner A., Neidhöfer S., Matthias T. Serological markers and/or intestinal biopsies in the case-finding of celiac disease. Editorial, Internat. J. Celiac dis. 2015;3:53-55.
[19]	Lerner A. Serological Diagnosis of Celiac Disease –Moving Beyond the Tip of the Iceberg. Internat. J. of Celiac Dis. Editorial. 2014;2:64-66.
[20]	Lerner A, Jeremias P, Matthias T. Outside of Normal Limits: False Positive/Negative Anti TG2 Autoantibodies. Internat J Celiac Disease, 2015;3:87-90.
[21]	Lerner A, Neidhöfer S, Matthias T. Transglutaminase 2 and anti transglutaminase 2 autoantibodies in celiac disease and beyond: Part A: TG2 double-edged sword: gut and extraintestinal involvement. Immunome Research, 2015;11:101-105.
[22]	Lerner A, Neidhöfer S, Matthias T. Transglutaminase 2 and anti transglutaminase 2 autoantibodies in celiac disease and beyond. Part B: Anti- Transglutaminase 2 autoantibodies: friends or enemies. Immunome Research, 2015;11:3-7.
[23]	Lerner A, Matthias T. Don’t forget the exogenous microbial transglutaminases: it is immunogenic and potentially pathogenic. Biophysics, 2016;3:529-535.
[24]	Schirru E, Jores RD, Congia M. Prudence is necessary in the application of the new ESPGHAN criteria for celiac disease omitting duodenal biopsy: a case report. Eur J Gastroenterol Hepatol. 2014;26:679-80.
[25]	Zevit N, Shamir R. Diagnosis of celiac disease: where are we heading after the ESPGHAN 2012 guidelines? J Pediatr Gastroenterol Nutr. 2014;59 Suppl 1:S13-5.
[26]	Barak M., Rozenberg O., Froom P., Grinberg M., Reginashvili D., Henig C., Pacht A., Lerner A. Challenging our serological algorithm for celiac disease (CD) diagnosis by the ESPGHAN guidelines. Clin Chem Lab Med. 2013;51:e257-259.
[27]	Vermeersch P, Geboes K, Mariën G, Hoffman I, Hiele M, Bossuyt X. Defining thresholds of antibody levels improves diagnosis of celiac disease. Clin Gastroenterol Hepatol. 2013;11:398-403
[28]	Tye-Din JA, Cameron DJ, Daveson AJ, Day AS, Dellsperger P, Hogan C et al. Appropriate clinical use of human leukocyte antigen typing for coeliac disease: an Australasian perspective. Intern Med J. 2015;45:441-50.
[29]	Atherton R, Ross A, Jessop F, Williams R, Heuschkel R, Zilbauer M. Coeliac disease in children with type 1 diabetes: are current guidelines proving difficult to implement in practice? J Pediatr Gastroenterol Nutr. 2014;59:600-3.
[30]	Gidrewicz D, Potter K, Trevenen CL, Lyon M, Butzner JD. Evaluation of the ESPGHAN Celiac Guidelines in a North American Pediatric Population. Am J Gastroenterol. 2015;110:760-7.
[31]	Dickey W, McMillan SA, Hughes DF. Sensitivity of serum tissue transglutaminase antibodies for endomysial antibody positive and negative coeliac disease. Scand J Gastroenterol. 2001;36:511-4.
[32]	Marsh MN, Johnson WM, Rostami K. Mucosal histopathology in celiac disease: a rebuttal of Oberhuber's sub-division of Marsh III. Gastroenterol Hepatol Bed Bench. 2015;8:99-109.
[33]	Lerner A, Matthias T. Intraepithelial lymphocyte normal cut-off level in celiac disease: The debate continues. Internat J Celiac Dis.2016;4:4-6.
[34]	Mubarak A, Nikkels P, Houwen R, Ten Kate F. Reproducibility of the histological diagnosis of celiac disease. Scand J Gastroenterol. 2011;46:1065-73.
[35]	Smarrazzo A, Misak Z, Costa S, Mičetić-Turk D, Abu-Zekry M, Kansu A, Abkari A, et al. Diagnosis of celiac disease and applicability of ESPGHAN guidelines in Mediterranean countries: a real life prospective study. BMC Gastroenterol. 2017;17:17.
[36]	Sugai E, Moreno ML, Hwang HJ, Cabanne A, Crivelli A, Nachman F, Vázquez H, et al. Celiac disease serology in patients with different pretest probabilities: is biopsy avoidable? World J Gastroenterol. 2010;16:3144-52.
[37]	Gujral N1, Freeman HJ, Thomson AB. Celiac disease: prevalence, diagnosis, pathogenesis and treatment. World J Gastroenterol. 2012;18:6036-59.
[38]	Bizzaro N1, Tozzoli R, Villalta D, Fabris M, Tonutti E. Cutting-edge issues in celiac disease and in gluten intolerance. Clin Rev Allergy Immunol. 2012;42:279-87.
[39]	Rozenberg O, Lerner A, Pacht A, Grinberg M, Reginashvili D, Henig C, Barak M. A novel algorithm for the diagnosis of celiac disease and a comprehensive review of celiac disease diagnostics. Clin Rev Allergy Immunol. 2012;42:331-41.
[40]	Rozenberg O, Lerner A, Pacht A, Grinberg M, Reginashvili D, Henig C, Barak M. A new algorithm for the diagnosis of celiac disease. Cell Mol Immunol.2011;8:146-9.
[41]	Volta U, Granito A, Parisi C, Fabbri A, Fiorini E, Piscaglia M, Tovoli F, Grasso V et al.Deamidated gliadin peptide antibodies as a routine test for celiac disease: a prospective analysis. Clin Gastroenterol. 2010;44:186-90.
[42]	Agardh D. Antibodies against synthetic deamidated gliadin peptides and tissue transglutaminase for the identification of childhood celiac disease. Clin Gastroenterol Hepatol. 2007;5:1276-81.
[43]	Niveloni S, Sugai E, Cabanne A, Vazquez H, Argonz J, Smecuol E, Moreno ML, Nachman F, Mazure R, et al. Antibodies against Synthetic Deamidated Gliadin Peptides as Predictors of Celiac Disease: Prospective Assessment in an Adult Population with a High Pretest Probability of Disease. Lin Chem 2007;53:2186-2192.
[44]	Holding S, Wilson F, Spradbery D. Clinical evaluation of the BioPlex 2200 Celiac IgA and IgG Kits - A novel multiplex screen incorporating an integral check for IgA deficiency. J Immunol Methods. 2014; 405:29-34.
[45]	Tozzoli R., Kodermaz G., Tampoia M., Visentini D., Tonutti E., Bizzaro N. [detection of autoantibodies specific for transglutaminase-gliadin peptides complex: a new way to explore the celiac iceberg.] It J Lab Med. 2010;6;28-35.
[46]	Matthias T., Pfeiffer S., Selmi C., Eric Gershwin M. Diagnostic challenges in celiac disease and the role of the tissue transglutaminase-neo-epitope. Clin Rev Allergy Immunol. 2010; 38:298-301.
[47]	Remes-Troche JM, Ramírez-Iglesias MT, Rubio-Tapia A., Alonso-Ramos A., Velazquez A., Uscanga LF. Celiac disease could be a frequent disease in Mexico: prevalence of tissue transglutaminase antibody in healthy blood donors. J Clin Gastroenterol. 2006;40:697-700.
[48]	Remes-Troche JM, Rios-Vaca A., Ramírez-Iglesias MT, Rubio-Tapia A., Andrade-Zarate V., Rodríguez-Vallejo F., López-Maldonado F., Gomez-Perez FJ, Uscanga LF. High prevalence of celiac disease in Mexican Mestizo adults with type 1 diabetes mellitus. J Clin Gastroenterol.2008; 42:460-5.
[49]	Lerner A, Jeremias P, Neidhöfer S, Matthias T. Antibodies against neo-epitope tTg complexed to gliadin are different and more reliable then anti-tTg for the diagnosis of pediatric celiac disease. J Immunol Methods. 2016;429:15-20.
[50]	Schirru E, Danjou F, Cicotto L, Rossino R, Macis MD, Lampis R et al. Anti-actin IgA antibodies identify celiac disease patients with a Marsh 3 intestinal damage among subjects with moderate anti-TG2 levels. Biomed Res Int. 2013;2013:630463.
[51]	Kumar V, Beutner EH, Lerner A, Jain N, Chorzelski TP. Comparison of disease specificity of antiendomysial and antigliadin antibodies. In: “Immunopathology of the skin”, Eds: EH Beutner, TP Chorzelski, V Kumar. John Wiley, New York, pp 483-488, 1987.
[52]	Rossi TM, Kumar V, Lerner A, Heitlinger LA, Tucker N, Fisher J. Relationship of endomysial antibodies to jejunal mucosa pathology: specificity towards both symptomatic and asymptomatic celiacs. J Pediatr Gastroenterol Nutr 1988;7:858-863.
[53]	Bizzaro N., Tozzoli R., Villalta D., Fabris M., Tonutti E. Cutting-edge issues in celiac disease and in gluten intolerance. Clin Rev Allergy Immunol. 2012; 42:279-87.
[54]	Matthias T., Pfeiffer S., Selmi C., Eric Gershwin M. Diagnostic challenges in celiac disease and the role of the tissue transglutaminase-neo-epitope. Clin Rev Allergy Immunol. 2010; 38:298-301.
[55]	Matthias T, Neidhöfer S, Pfeiffer S, Prager K, Reuter S, Gershwin ME. Novel trends in celiac disease. Cell Mol Immunol. 2011;8: 121-5.
[56]	Porcelli B, Ferretti F, Vindigni C, Terzuoli L. Assessment of a Test for the Screening and Diagnosis of Celiac Disease. J Clin Lab Anal. 2016;30:65-70.
[57]	Lytton SD, Antiga E, Pfeiffer S, Matthias T, Szaflarska-Poplawska A, Ulaganathan VK, Placek W, Fabbri P, Hall R, Caproni M. Neo-epitope tissue transglutaminase autoantibodies as a biomarker of the gluten sensitive skin disease--dermatitis herpetiformis. Clin Chim Acta. 2013 ;415:346-9.
[58]	Lerner A, Neidhöfer S, Jeremias P, Matthias T. The diversities between the neo-epitope and the IgA- tissue transglutaminase autoantibodies in celiac disease. In: Autoantigens, autoantibodies, autoimmunity. Volume 10th , Eds: K Conrad, Chan EKL, Andrade LEC, Steiner G, Pruijn GJM, Y Shoenfeld. Page 220-226, e-pub, 2015.
[59]	Lerner A, Matthias T. Possible association between celiac disease and bacterial transglutaminase in food processing: a hypothesis. Nutr Rev. 2015;73:544-552.
[60]	Lerner A, Matthias T. Changes in intestinal tight junction permeability associated with industrial food additives explain the rising incidence of autoimmune disease. Autoimmun Rev. 2015;14:479-89.
[61]	Lerner A, Matthias T. Microbial transglutaminase is a potential environmental inducer of celiac disease. In: From Autoantibody Research to Standardized Diagnostic Assays in the Management of Human Diseases. Volume 10th, Eds: K Conrad, Chan EKL, Andrade LEC, Steiner G, Pruijn GJM, Y Shoenfeld. 12th symposium on autoantibodies, 2015, Dresden, Germany. Page 227-233, Pabst Science Publishers, Lengerich, Germany, e-pub.
[62]	Matthias T, Jeremias P, Neidhöfer S, Lerner A. The industrial food additive microbial transglutaminase, mimics the tissue transglutaminase and is immunogenic in celiac disease patients. Autoimmun Rev, 2016;15:1111-1119.
[63]	Lerner A, Matthias T. Are Microbial Enzymes Used Safe in the Processed Food Industries? Food and Bioprocess Technology, 2016;9: 2125-2126.